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Early-onset and classical forms 
of type 2 diabetes show impaired 
expression of genes involved in 
muscle branched-chain amino acids 
metabolism
María Isabel Hernández-Alvarez1,2,3, Angels Díaz-Ramos1,2,3, María Berdasco4, Jeff Cobb5, 
Evarist Planet1, Diane Cooper7, Agnieszka Pazderska6, Krzystof Wanic6, Declan O’Hanlon6, 
Antonio Gomez4, Laura R. de la Ballina1,2, Manel Esteller4, Manuel Palacin1,2,8, Donal J. 
O’Gorman7, John J. Nolan9 & Antonio Zorzano1,2,3
The molecular mechanisms responsible for the pathophysiological traits of type 2 diabetes are 
incompletely understood. Here we have performed transcriptomic analysis in skeletal muscle, and 
plasma metabolomics from subjects with classical and early-onset forms of type 2 diabetes (T2D). 
Focused studies were also performed in tissues from ob/ob and db/db mice. We document that T2D, 
both early and late onset, are characterized by reduced muscle expression of genes involved in 
branched-chain amino acids (BCAA) metabolism. Weighted Co-expression Networks Analysis provided 
support to idea that the BCAA genes are relevant in the pathophysiology of type 2 diabetes, and that 
mitochondrial BCAA management is impaired in skeletal muscle from T2D patients. In diabetic mice 
model we detected alterations in skeletal muscle proteins involved in BCAA metabolism but not in 
obese mice. Metabolomic analysis revealed increased levels of branched-chain keto acids (BCKA), and 
BCAA in plasma of T2D patients, which may result from the disruption of muscle BCAA management. 
Our data support the view that inhibition of genes involved in BCAA handling in skeletal muscle takes 
place as part of the pathophysiology of type 2 diabetes, and this occurs both in early-onset and in 
classical type 2 diabetes.
Type 2 diabetes mellitus is associated with alterations in glucose and lipid metabolism in skeletal muscle1. Some 
of those alterations are secondary to insulin resistance, which in turn, has been explained by defects at one or 
several levels of the insulin signaling cascade2,3. Thus, glucose transport or glycogen synthesis are defective, which 
leads to reduced glucose uptake in muscle in type 2 diabetic patients4–6. In addition, type 2 diabetes is associated 
with mitochondrial dysfunction, and reduced expression of PGC-1alpha7–10. There is significant variability in the 
pathophysiology of type 2 diabetes with varying implications for insulin signalling and energy metabolism in 
skeletal muscle11. In this regard, we have previously reported that early-onset very obese type 2 diabetic patients 
failed to improve VO2max and had no improvement in whole-body insulin sensitivity in response to an exercise 
intervention12. In keeping with the possibility that chronic exercise training failed to activate a mitochondrial 
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oxidative response in young type 2 diabetes, acute exercise did not induce PGC-1alpha gene expression, and 
chronic exercise did not induce Mfn2 expression in early-onset type 2 diabetic patients13.
Branched-chain amino acids (BCAAs), leucine, isoleucine and valine, are essential amino acids. Due to essen-
tiality, rates of tissue utilization are exquisitely regulated in humans. It is also known that obesity and type 2 
diabetes show alterations in BCAAs plasma levels14. Obese and insulin-resistant individuals show higher serum 
BCAAs than their lean and insulin-sensitive counterparts15–17. In addition, type 2 diabetic patients show higher 
levels of BCAA compared to nondiabetic subjects18. Notably, high plasma levels of BCAAs predict the develop-
ment of type 2 diabetes19. These alterations in systemic BCAAs have been discussed as a consequence of insulin 
resistance20, although the mechanisms remain unexplained14,21. Interestingly, it has also been proposed that alter-
ations in BCAA availability or metabolism may influence metabolic homeostasis. Regarding to skeletal muscle. 
BCAAs and more specifically leucine stimulate mTORC1 activity, also known as mammalian target of rapamycin 
complex 1, a protein complex that functions as a nutrient sensor and controls cell growth22–24. mTORC1 also 
stimulates protein synthesis and inhibits autophagy25,26. It has been recently reported that the BCAA metabolite 
3-hydroxyisobutyrate is secreted from muscle and causes insulin resistance27. Furthermore, alterations in the 
metabolism of BCAA in mice heterozygous for the BCAA enzyme methylmalonyl-CoA mutase was linked to 
impaired lipid metabolism28.
In this manuscript we have identified additional pathophysiological traits in classical and in early-onset forms 
of type 2 diabetes, through the use of transcriptomic analysis in skeletal muscle and plasma metabolomics. We 
document that those different forms of T2D are characterized by reduced muscle expression of genes involved in 
branched-chain amino acids (BCAA) handling.
Materials and Methods
Study subjects. Patients attending either the endocrinology or diabetes services at St James’ Hospital, Dublin 
and had obesity or type 2 diabetes, were invited to take part in the study. The study protocol was approved by 
the local Research Ethics Committee and a consent was obtained from all participants. Funding was provided 
through DEXLIFE, an EU FP7 project (grant agreement no: 279228). The project was approved by the ‘Joint St. 
James’s Hospital and Adelaide and Meath Hospital Ethics Committee’ reference number 2008/06/03.
Early onset type 2 diabetes was defined as onset of the disease before 30 years of age. Subjects with co-existing 
illnesses or secondary forms of diabetes were excluded. Classical onset was defined as disease onset after 50 years 
of age. All recruited patients were obese (BMI > 30) and weight stable, had negative glutamic acid decarboxylase 
(GAD) antibodies and normal or high fasting c-peptide concentrations at diagnosis (C-peptide ≥ 2.5 ng/ml). 
Exclusion criteria included a history of ketosis or ketoacidosis, pregnancy, active cancer and use of corticoster-
oids. Healthy, obese controls with normal glucose tolerance and no family history of diabetes were recruited from 
endocrine clinics at St James’s Hospital, and through Dublin City University by local advertisement. All subjects 
were sedentary at baseline (determined using the International Physical Activity Questionnaire – Long Format), 
with a low VO2max. All gave written informed consent for the study which had been approved by the local 
Research Ethics Committee. Clinical characteristics of both groups of subjects, is summarized in Table 1. Family 
history was positive for diabetes in a 1st degree relative in 46% and 39% of patients with early- and classical-onset 
type 2 diabetes, respectively. The duration of diabetes prior to study enrollment was 2.1 years for early-onset and 
4.8 years for classical-onset disease. Patients had stable blood glucose concentrations at enrolment, with 88% 
of early onset type 2 diabetes subjects, and 78% of classical diabetes subjects treated with oral glucose lowering 
medications. Insulin was administered by 23% and 17% of early- and classical-onset type 2 diabetes participants, 
respectively.
Studies were done as previously described12,13. A maximum oxygen consumption capacity (VO2max) test was 
used to assess aerobic capacity and fitness. The maximal progressive incremental test to exhaustion was performed 
using a computer controlled electromagnetically braked medical assessment bicycle ergometer (Ergoselect 100, 
Ergoline). Open-circuit indirect calorimetry (Innocor INN00500, Innovision) was used for breath-by-breath res-
piratory gas analysis and to determine ventilation through a connected silicone rubber mouthpiece. Subjects were 
instructed to maintain a cycling cadence of 70 to 80 revolutions per minute, with the workload at level 1 set at 50 
Watts and increased by 25 Watts every 3 minutes until volitional exhaustion. Blood pressure and heart rate were 
measured throughout. The test was considered maximal if two of the following criteria were satisfied: a maximal 
Early-onset type 2 diabetes Classical type 2 diabetes
Control 
subjects




Older type 2 
diabetic subjects
n 12 21 17 24
Male/female ratio 9/3 14/7 7/10 18/6
Age (years) 23.82 ± 5.81 28.38 ± 3.86* 54.5 ± 6.09 55.04 ± 6.51
BMI (kg/m2) 35.66 ± 4.44 35 ± 9.66 33.37 ± 3.79 35.17 ± 4.72
Fasting glucose (mmol/l) 5.04 ± 0.51 9.08 ± 2.82* 5.02 ± 0.68 9.60 ± 2.69*
Fasting insulin (pmol/l) 29.59 ± 44.81 31.29 ± 34.64 12.03 ± 7.41 26.97 ± 22.26*
VO2max (ml*kg-1*min-1) 24.43 ± 4.02 24.17 ± 5.47 20.29 ± 5.03 21.93 ± 4.94
Table 1. Anthropometric and metabolic parameters measured in control and Type 2 diabetic subjects either 
Early-onset or classical Type 2 diabetes. Data are means ± standard deviation. Statistical analyses comparing 
control and type 2 diabetes state were performed by unpaired t-Test.
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heart rate equal to or greater than 95% of predicted maximal heart rate (220 - age), a respiratory exchange ratio 
greater than 1.1, or a levelling off in oxygen consumption in spite of further increases in power output.
Microarray assays. Microarray services were provided by the IRB Functional Genomics Core Facility, 
including quality control tests of total RNA by Agilent Bioanalyzer and Nanodrop spectrophotometry. Briefly, 
cDNA library preparation and amplification were performed from 25 ng total RNA using WTA2 (Sigma-Aldrich) 
with 17 cycles of amplification. 8 µg cDNA were subsequently fragmented by DNaseI and biotinylated by terminal 
transferase obtained from GeneChip Mapping 250 K Nsp Assay Kit (Affymetrix). Hybridization mixture was pre-
pared according to Affymetrix protocol. Each sample was hybridized to a PrimeView Human array (Affymetrix). 
Arrays were washed and stained in a Fluidics Station 450 (Fluidics protocol FS450_002) and scanned in a 
GeneChip Scanner 3000 (both Affymetrix) according to manufacturer’s recommendations. CEL files were gener-
ated from DAT files using GCOS software (Affymetrix). Normalized expression intensities were computed from 
Affymetrix CEL files using the RMA algorithm29. Microarray pre-processing was performed using R package (R 
Core Team (2014) (see Supplementary Statistical Analysis section).
Metabolomics. For absolute quantitation, metabolites were analyzed by isotope dilution UHPLC-MS/MS 
assays. In brief, 50 µl of EDTA plasma was spiked with stable labeled internal standards and subsequently sub-
jected to protein precipitation by mixing with 200 µl of 1% formic acid in methanol. Following centrifugation, ali-
quots of clear supernatant were injected onto an Agilent 1290/AB Sciex QTrap 5500 mass spectrometer LC-MS/
MS system equipped with a turbo ion-spray source using two different chromatographic systems (mobile phase/
column combinations). 3-Methyl-2-oxobutyric acid, 3-methyl-2-oxovalerate, and 4-methyl-2-oxopentanoic acid 
were eluted with a gradient (mobile phase A: 0.01% formic acid in water; mobile phase B: acetonitrile/methanol 
1:1) on a Waters Acquity C-18 BEH column (2.1 mm × 100 mm, 1.7 µm particle size) and detected in negative 
mode. Isoleucine, leucine, and valine were eluted with a gradient (mobile phase A: 0.05% perfluoropentanoic 
acid in water; mobile phase B: 0.05% perfluoropentanoic acid in acetonitrile) on a Waters Acquity C-18 BEH 
column (2.1 mm × 100 mm, 1.7 mm particle size) and detected in positive mode. Quantitation was performed 
based on the area ratios of analyte and internal standard peaks using a weighted linear least squares regression 
analysis generated from fortified calibration standards in water, prepared immediately prior to each run. Stable 
isotope labeled compounds 3-Methyl-2-oxobutyric acid -d7, 4-methyl-2-oxopentanoic acid -d3 (used for both 
3-methyl-2-oxovalerate and 4-methy-2-oxopentanoic acid), isoleucine-13C6, leucine-d3, valine-13C5-15N, were 
used as internal standards.
Mouse models. All animal work was approved and conducted according to guidelines established. This pro-
ject has been assessed favourably by the Institutional Animal Care and Use Committee from Parc Cientific de 
Barcelona (IACUC-PCB) and the IACUC considers that the above-mentioned project complies with standard 
ethical regulations and meets the requirements of current applicable legislation (RD 53/2013 Council Directive; 
2010/63/UE; Order 214/1997/GC).
Statistical analysis. Differential expression analysis of microarray data was performed using GaGa (Rossell 
D. (2009). “GaGa: a Parsimonious and Flexible Model for Differential Expression Analysis.” Annals of Applied 
Statistics, 3, pp. 1035-1051) using a 5% FDR and a minimum 1.2 fold-change between groups. Microarray data 
were adjusted for batch and gender. Relevant results for differential expression analysis were represented in a 
heatmap showing expression values centered and scaled across samples. In the heatmap, samples and probe-
sets were represented under an hierarchical clustering in which correlation distance and Ward agglomeration 
method was used. Gene set enrichment was assessed through Bayesian enrichment (Mallick, B. K., Gold, D. & 
Baladandayuthapani, V. Bayesan Analysis of Gene Expression Data (Wiley, 2009)). One thousand posterior sam-
ples were generated to be used in the differential expression indicator, according to the posterior probabilities of 
differential expression obtained from pairwise comparisons. For each gene set we computed the probability of 
enrichment as the proportion of posterior samples for which the percentage of differentially expressed genes in 
the set was larger than the percentage of differentially expressed genes in the rest of the genome.
To measure the association between gene expression and plasma metabolites, Pearson Correlation Coefficients 
and their corresponding assymptotic 95% confidence intervals and p-values were computed. Correlation coeffi-
cients were presented in a symmetric heatmap after clusterization with euclidean distance and Ward agglomer-
ation method.
Results
Clinical and metabolic characteristics. The clinical and metabolic characteristics of the four study groups 
are presented in Table 1. All groups were obese and were matched for body mass index (BMI). The Old and Young 
T2 diabetes groups had significantly higher fasting blood glucose. Maximal aerobic capacity (VO2 max) was sim-
ilar within the age categories but was lower overall for the older compared to the younger groups.
Identification of gene expression signatures that are common in early-onset and classical forms 
of type 2 diabetes. The global expression profile of muscles from control (YC and OC) and type 2 diabetic 
patients (YT2, and OT2) was identified by microarray analysis. In classical type 2 diabetic patients we identi-
fied 790 genes that underwent dysregulation (366 over-expressed, and 424 under-expressed) (Supplementary 
Table 1), whereas in early-onset type 2 diabetic patients we identified 449 dysregulated genes (268 over-expressed, 
and 181 under-expressed) (Supplementary Table 1). Interestingly, a significant proportion of genes (333) were 
dysregulated in both groups of patients (pv 2.22e-16). From those, 213 genes showed over-expression in type 
2 diabetic patients while 120 were under-expressed compared to control subjects (Fig. 1a and Supplementary 
Table 1). As a result of this analysis, a clear gene signature in skeletal muscle from type 2 diabetes patients is seen 
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in the clustering heatmap shown in Fig. 1b. We acknowledge some limitations in our study namely sex unbal-
ance between obese and type 2 diabetic subjects. These limitations have been partially neutralized by adjusting 
microarray data for gender. Gene Set Enrichment Analysis (GSEA) revealed that genes dysregulated in both 
classical and early-onset type 2 diabetic patients were enriched in metabolic pathways such as the metabolism of 
amino acids (BCAA, arginine and proline), fatty acids, pyrimidines or peroxisomes (Fig. 1c).
Weighted Co-expression Networks Analysis (WGCNA) reveals the relevance of the BCAA genes 
in the pathophysiology of type 2 diabetes. To analyze the gene signature found for type 2 diabetes 
patients in a deep manner we decided to mix control groups or type 2 diabetic groups independently of age 
(young and old together). The clinical and metabolic characteristics of this rearrangement are presented in 
Table 2. Next, we analyzed the potential relevance of BCAA genes and the interaction between BCAA metabolic 
genes and other metabolic genes by Weighted Co-expression Networks Analysis (WGCNA). WGCNA is a useful 
tool to describe the pairwise relationships among gene transcripts and to unravel genetic mechanisms of com-
plex diseases30–32. Thus, we selected the most relevant gene sets obtained in GSEA (Supplementary Table 2), and 
the genes of those categories were subjected to WGCNA. This permitted the generation of a gene co-expression 
network (Fig. 2a). The TOM heatmap graph shows the existence of co-expression interconnectedness, which 
is indicated by progressively more saturated yellow and red colors, and a total of 13 modules were identified 
(different colors in Fig. 2a). Clustering Analysis on Eigengene Network adjacencies revealed the existence of 
Figure 1. Early-onset and classical forms of type 2 diabetes generate a gene signature. (a) Venn diagram 
depicting genes differentially expressed in muscle from type 2 diabetic patients compared with muscle from 
age- and BMI-matched nondiabetic subjects. (b) Heatmap of genes differentially expressed in muscle from type 
2 diabetic patients. YT2 are early-onset type 2 diabetic subjects; OT2 are older type 2 diabetic subjects, and their 
respective controls are YC and OC. (c) GSEA of genes dysregulated in muscles from type 2 diabetic patients.
Control 
subjects
Type 2 diabetes 
subjects
n 29 45
Male/female ratio 16/13 32/13
Age (years) 42 ± 16.45 42.6 ± 14.49
BMI (kg/m2) 34.3 ± 4.15 35.09 ± 7.36
Fasting glucose (mmol/l) 5.02 ± 0.60 9.36 ± 2.74*
Fasting insulin (pmol/l) 19.46 ± 30.2 29.45 ± 28.5
VO2max (ml*kg-1*min-1) 21.88 ± 5.02 22.97 ± 5.25
Table 2. Anthropometric and metabolic parameters measured in control and Type 2 diabetic subjects. Data are 
means ± standard deviation. Statistical analyses comparing control and type 2 diabetes state were performed by 
unpaired t-Test.
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module relationships and defined four different groups of modules (meta-modules) (Fig. 2b): Red, Greenyellow 
and Yellow modules (meta-module A); Brown, Blue and Turquoise (meta-module B); Pink, Green, Etan and 
Magenta (meta-module C); and Purple, Black and Salmon modules (meta-module D). Most of the modules in 
meta-modules A and B showed a significant association with type 2 diabetes and a strong correlation between 
gene module-membership (MM), connectivity and gene significance, the later measured as the t-statistic from 
a linear model (Fig. 2c,d for the Blue module). From those, the Blue module was enriched in gene sets of BCAA 
and Fatty acid metabolism genes (Supplementary Table 3). Interestingly, the Green module was also enriched in 
BCAA genes although no association with type 2 diabetes was found. A graph representation with the strongest 
connections of the blue module genes highlight the central role of BCAA genes as BCAT2, HMGCL, ACAA2, 
ACAD8, HADHB or ACADS in this sub-network (Supplementary Figure 1). In all, this statistical analysis further 
suggests the relevance of the BCAA genes in the pathophysiology of type 2 diabetes.
Type 2 diabetes is characterized by reduced muscle expression genes encoding enzymes of 
BCAA metabolism. Based on the GSEA and WGCNA data obtained in previous sections, we next per-
formed real-time PCR assays to analyze the expression of genes encoding enzymes of BCAA metabolism in 
muscle from the pooled control and type 2 diabetic groups to validate the microarray analysis. As shown in Fig. 3, 
when compared to BMI-matched obese controls, type 2 diabetes is characterized by reduced expression of genes 
encoding for the mitochondrial steps of BCAA metabolism BCAT2, and BCKDHB (encoding the E1beta subunit 
of BCKD) (Fig. 3a,b). However, no changes were observed in the mRNA expression of BCKDHA in the diabetic 
groups (Fig. 3b). To further analyze the nature of the defective BCAA gene expression in diabetic muscle, the 
same group of patients was analyzed for differential methylation in genes involved in BCAA metabolism. This 
analysis revealed an increased methylation in the gene encoding the E1beta subunit of BCKD in type 2 diabetic 
patients (Supplementary Figure 2), which is consistent with the reduced gene expression detected under these 
conditions (Fig. 3c).
We also analyzed the groups separately according to age, as shown in Supplementary Figure 3. Early-onset 
type 2 diabetes was characterized by reduced expression of BCAT2 (Supplementary Figure 3B,C). In type 2 diabe-
tes of older subjects a reduced expression was also detected for BCKDHB (Supplementary Figure 3C). Thus, both 
classical and early-onset type 2 diabetes are characterized by reduced skeletal muscle expression of BCAA genes.
Figure 2. Identification of gene co-expression modules in human skeletal muscle from control and type 2 
diabetic patients by WGCNA analysis. (a) Network heatmap plot. Branches of the cluster dendrogram of the 
most connected genes gave rise to a number of gene co-expression modules. (b) Heatmap plot of the adjacencies 
in the eigengene network. Each row and column in the heatmap corresponds to one module eigengene (labeled 
by color). In the heatmap, blue color represents low adjacency (negative correlation), while red represents high 
adjacency (positive correlation). Panels c, and d. Scatterplots of gene significance versus module connectivity 
(panel c) or module membership (panel d) in the Blue module. BCAA genes are shown in red color.
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Plasma metabolomics supports the view for a defect in branched-chain amino acid handling 
in type 2 diabetes. Metabolomic analysis performed in plasma of the same subjects, showed a signifi-
cant accumulation of BCAAs in type 2 diabetes compared with non-diabetic subjects. Plasma leucine, valine, 
and isoleucine levels were elevated in subjects with type 2 diabetes relative to control group (Fig. 3d–f). More 
importantly, the 2-keto acids of all BCAAs (BCKAs) (3-methy-2-oxobutyrate, 3-methyl-2-oxovalerate, and 
4-methyl-2-oxopentanoate), which are the substrates for BCKD, were also markedly elevated in plasma from 
type 2 diabetics (Fig. 3g–i).
When we analyzed the groups according to age, no significant differences for BCAAs and their 2-keto acids 
was observed for early onset type 2 diabetes and old subjects with type 2 diabetes. Only 3-methyl-2-oxobutyrate 
levels were increased statistically significant in both groups of diabetic subjects (Supplementary Figure 3D–I). 
Old type 2 diabetic subjects also showed statistically greater levels of valine, isoleucine, and the other 2-keto acids 
(4-methyl-2-oxopentanoate and 3-methyl-2oxovalerate) (Supplementary Figure 3D–I).
Plasma BCAAs and their catabolites negatively correlate with gene expression of BCAA 
enzymes in type 2 diabetic patients. To get some insight into the capacity of the T2D patients to metab-
olize BCAA as compared to non-diabetic subjects, correlation analyses were performed between plasma BCAA 
and their corresponding catabolites detected by metabolomics, and the microarray data from muscle transcrip-
tomics. Results for these analyses showed a negative correlation between most of the plasma metabolites and 
transcripts linked to BCAA metabolism in skeletal muscle (Fig. 4, and Supplementary Table 4). In addition, sim-
ilar correlations were detected when plasma metabolomics were analyzed with real time PCR expression levels 
of transcripts encoding for BCAA catabolizing enzymes assessed in skeletal muscle biopsies. (Supplementary 
Figure 4, and Supplementary Table 5). These data permit to propose that alterations in the expression of genes 
encoding enzymes involved in BCAA metabolism lead to enhanced release and greater circulating levels of BCAA 
and their metabolites.
Figure 3. Skeletal muscle gene expression of branched chain amino acids mitochondrial proteins in type 2 
diabetic subjects (T2D) and their respective matched control groups (C). Real-time PCR was performed in 
skeletal muscle biopsies: (a) BCAT2, (b) BCKDHA, and (c) BCKDHB); Plasma metabolomics was performed 
in the same subjects and relative values are shown: (d) Leucine, (e) Valine, (f) Isoleucine and catabolites (g) 
4-methyl-2-oxopentanoate, (h) 3-methyl-2-oxobutyrate and (i) 3-methyl-2-oxovalerate. Data are presented as 
mean ± standard deviation. Statistical analyses comparing type 2 diabetic subjects vs respective controls were 
performed by unpaired t-test *p < 0.05.
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Ob/ob obese mice show elevated plasma BCAAs and alter protein levels of BCAA enzymes in 
liver and adipose tissue but not in muscle. To document whether the situation on BCAAs in human 
subjects was similar to that occurring in mouse models of obesity/insulin resistance, we analyzed the profile of 
BCAAs in obese ob/ob mice and their respective lean controls. To do so we performed focused metabolomics 
in plasma and measured the expression of BCAA metabolizing enzymes in skeletal muscle, liver and white adi-
pose tissue (WAT). As shown in Fig. 5a, the plasma levels of BCAA leucine, valine and isoleucine were two-fold 
higher in ob/ob mice compared to their controls. Moreover, increased plasma levels of 4-methyl-2 oxopentanoate 
(BCKA derived from leucine) and 3-methyl-2 oxovalerate (BCKA from isoleucine) were also detected in ob/ob 
mice (Fig. 5b). However no changes were found in 3-methyl-2-oxobutyrate which is the BCKA derived from 
valine (Fig. 5b).
Expression of the genes encoding BCAA degradation enzymes such as the mitochondrial transaminase 
(BCAT2) and the subunits alpha and beta of BCKD (BCKDHA and BCKDHB) was unaltered in muscle from ob/
ob mice compared with controls (Fig. 5c–e). To analyze the potential impact of methylation on gene expression, 
we performed quantitative analysis of methylation in genes encoding for BCAA metabolism. Data revealed that 
the BCAT2 gene is highly methylated in the livers of control mice (Supplementary Figure 5A,C), which is consist-
ent with the lack of BCAT2 expression in liver. No changes in methylation of BCAT2 gene was detected in livers 
from ob/ob mice (Supplementary Figure 5E). The BCAT2 gene was not methylated in muscle or in white adipose 
tissue, which was in parallel to a substantial gene expression (Supplementary Figure 5D). BCKDHA gene was 
barely methylated in all tissues studied (Supplementary Figure 5B).
According with prior reports33, no changes in the muscle of BCAT2 or BCKDHA proteins levels or in the 
phosphorylation of the subunit E1a of BCKDHA complex were detected in ob/ob respect to control mice (Fig. 5f). 
However, the phosphorylation level of BCKDHA was twofold greater in the liver from ob/ob mice, which indi-
cates a lower activity compared to controls (Fig. 5g). In WAT we detected a reduced expression of BCKDHA and 
BCAT2 in ob/ob mice (Fig. 5h).
Overall, our results support the view that the higher plasma levels of BCAAs detected in obesity/insulin resist-
ance ob/ob mice are a consequence of reduced protein expression of BCAA metabolism enzymes in liver and 
white adipose tissue, and occur in the absence of alterations in skeletal muscle.
Db/db diabetic mice show alterations in muscle protein levels of BCAA degradation enzymes 
and elevated plasma BCAA α-keto acids. Next, we performed focused plasma metabolomics and 
assayed the expression of BCAA metabolizing enzymes in diabetic db/db mice compared to control mice. Plasma 
levels of BCAAs, leucine and isoleucine were enhanced in db/db mice compared to the control group (Fig. 6a). 
Figure 4. Plasma metabolomics correlation with skeletal muscle gene expression. Correlation analysis of 
plasma branched chain amino acids and their catabolites with gene expression (obtained in microarray) of 
enzymes involved in the catabolism of branched chain amino acids in skeletal muscle. Statistics is shown in 
Supplementary Table 5.
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Figure 5. Characterization of obese, insulin resistant ob/ob mice. (a) Plasma content of branched chain 
amino acids from control and ob/ob mice. (b) Plasma content of keto acids from control and ob/ob mice. 
(c–e) mRNA relative values of mitochondrial genes involved in catabolism of branched chain amino acids in 
skeletal muscle from control and ob/ob mice. (f) Skeletal muscle (SKM) phosphorylation, protein levels and 
quantification of mitochondrial branched chain amino acids catabolic enzymes from control and ob/ob mice. 
(g) Liver phosphorylation, protein levels and quantification of mitochondrial branched chain amino acids 
catabolic enzymes from control and ob/ob mice. (h) White adipose tissue (WAT) phosphorylation, protein 
levels and quantification of mitochondrial branched chain amino acids catabolic enzymes from control and 
ob/ob mice. The images are cropped from full blots, which are shown in Supplementary Information. Data 
are means ± SEM. Statistical analyses comparing ob/ob mice vs controls were performed by unpaired t-test 
*p < 0.05.
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In addition, plasma levels of all of three alpha-keto acids (4-methyl-2 oxopentanoate, 3-methyl-2-oxobutyrate 
and 3-methyl-2 oxovalerate) were increased in db/db mice (Fig. 6b). Further statistical analysis revealed a slight 
decrease in the plasma levels of isoleucine in db/db animals compared to ob/ob, that was in parallel to the increase 
observed in the 3-methyl-2-oxovalerate (the alpha-ketoacid of isoleucine) (Supplementary Figure 6). The pattern 
of changes in BCAA and BCKA found in diabetic mice was very similar to the signature detected in human type 
2 diabetes.
In keeping with the observations in ob/ob mice, the phosphorylation level of BCKDHA was twofold greater 
in livers from db/db mice, which indicates a lower activity (Fig. 6g), and a reduced expression of BCKDHA and 
BCAT2 in WAT were detected in db/db mice (Fig. 6h).
In skeletal muscle, the expression of genes encoding BCKDHA and BCKDHB only showed a trend to decrease 
in the db/db group (Fig. 6c–e), and the total levels of BCKDHA was reduced in db/db mice (Fig. 6f) (50% reduced 
compared to the control group). Under these conditions, an increased muscle BCAT2 protein was detected in 
db/db mice (Fig. 6f). Our data indicate that diabetic db/db mice may be a good model of type 2 diabetes, and 
are characterized by reduced muscle BCAA degradation due to a lower level of BCKDHA subunit complex, and 
increased levels of the transaminase (BCAT2). This may explain the greater plasma levels of BCKAs found in db/
db mice and in type 2 diabetic patients.
Discussion
Early-onset type 2 diabetes is typically characterized by obesity and severe insulin resistance in young people with 
a strong family history of type 2 diabetes34,35. In prior publications, we reported that early-onset type 2 diabetic 
patients do not improve VO2max in response to an exercise intervention, and in parallel, acute exercise does not 
induce muscle PGC-1alpha gene expression, and chronic exercise does not induce muscle mitochondrial Mfn2 
expression12,13. However, almost nothing is known about the physiology of the skeletal muscle on early-onset type 
2 diabetes.
The metabolism of BCAAs is a highly regulated process, and loss of ability to metabolize them causes maple 
syrup urine disease in humans36. Skeletal muscle is also the major organ extracting an intravenous leucine37. 
Figure 6. Characterization of diabetic db/db mice. (a) Plasma content of branched chain amino acids from 
control and db/db mice. (b) Plasma content of keto acids from control and db/db mice. (c–e) mRNA relative 
values of mitochondrial genes involved in catabolism of branched chain aminoacids in skeletal muscle 
from control and db/db mice. (f) Skeletal muscle (SKM) phosphorylation, protein levels and quantification 
of mitochondrial branched chain aminoacids catabolic enzymes from control and db/db mice. (g) Liver 
phosphorylation, protein levels and quantification of mitochondrial branched chain aminoacids catabolic 
enzymes from control and db/db mice. (h) White adipose tissue (WAT) phosphorylation, protein levels and 
quantification of mitochondrial branched chain amino acids catabolic enzymes from control and db/db mice. 
The images are cropped from full blots, which are shown in Supplementary Information. Data are mean ± SEM. 
Statistical analyses comparing control vs db/db mice were performed by unpaired t-test *p < 0.05.
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Muscle has the capacity to oxidize BCAAs and BCKAs or to release their metabolites into the circulation. Thus, 
it has been recently identified that 3-hydroxyisobutyrate is released from muscle and causes insulin resistance27. 
Our results revealed increased circulating concentrations of BCAA and their alpha-keto acids as well as a reduced 
expression of genes involved in BCAA metabolism. In addition, our data showed a negative correlation between 
the increased levels of plasmatic BCAAs, and their metabolites, and the reduced expression of genes encoding 
BCAA enzymes in type 2 diabetes. This suggests that the alterations occurring in muscle have an impact on the 
circulating levels of BCAAs and their metabolites. Then, we propose that different forms of type 2 diabetes or pro-
gression to different forms of type 2 diabetes reduce the handling of BCAAs in skeletal muscle. An impaired mito-
chondrial BCAA catabolism in skeletal muscle could also cause a potential release of BCAAs and their BCKAs 
from muscle to the circulation in type 2 diabetic conditions.
Our data in mice models support the view that skeletal muscle does not alter BCAA gene expression under 
conditions of insulin resistance alone. In this respect, it operates differentially from liver and adipose tissues 
which reduce BCAAs metabolism under insulin resistant conditions. Instead, BCAA metabolism is reduced in 
skeletal muscle during the stage of frank type 2 diabetes. In this connection, it has been reported that branched 
chain keto acids (BCKAs) can inactivate 2-ketoglutarate and pyruvate dehydrogenase complexes in muscle38. In 
addition, the effects of BCKAs inhibits pyruvate dehydrogenase flux leaving the most of the pyruvate dehydroge-
nase in the inactive form in liver39 and since the mitochondrial pyruvate dehydrogenase complex (PDC) controls 
the rate of carbohydrate oxidation, impairment of PDC activity mediated by high-fat intake has been advocated as 
a causative factor for the skeletal muscle insulin resistance, metabolic syndrome, and the onset of type 2 diabetes 
(T2D)40.
In contrast, studies performed in C. elegans indicate that silencing of the gene ortologous to BCAT1 enhances 
lifespan, which is dependent on higher levels of BCAAs, and neuroendocrine repression of TGFbeta (Mansfeld et 
al., Nat. Commun. 2015). This suggests the possibility that enhanced levels of BCAAs and their alpha-keto acids 
may show benefitial effects in humans.
In agreement with our results, Giesbertz and colleagues found that plasmatic levels of BCAA were upregulated 
in both ob/ob and db/db mice41. Regarding BCAA metabolites, Giesbertz et al. documented enhanced plasma 
levels of 3-hydroxyisobutyrate (a metabolite of the BCAA degradation pathway) in db/db mice but not in the 
ob/ob group. In addition, they found enhanced plasma levels of α-ketoisocaproic acid (the alpha-ketoacid from 
leucine) both in ob/ob and in db/db mice, while our results only showed a moderate increase in db/db mice 
compared to control. The differences between Giesbertz et al. and our study could be explained by the age of the 
mice. Thus, Giesbertz and colleagues studied mice at 20 weeks of age, whereas our analysis was done at 8 weeks 
of age, and it is likely that insulin resistance gets worse with age leading to larger differences in plasma metabo-
lites. Another interesting angle covered by Giesbert et al., was the correlation analysis between plasma and tissue 
metabolites in ob/ob and db/db41. This analysis revealed a correlation between BCAAs and metabolites in plasma 
and adipose tissue or in liver suggesting a role of these tissues in the alterations detected in BCAA metabolites in 
plasma. Our data also support the view that the higher plasma levels of BCAAs detected in obesity/insulin resist-
ance ob/ob mice are a consequence of reduced protein expression of BCAA metabolism enzymes in liver and 
white adipose tissue. In addition, our data indicate that diabetic db/db mice are characterized by reduced muscle 
BCAA degradation due to a lower level of BCKDHA subunit complex, and increased levels of the transaminase 
(BCAT2), and this may explain the greater plasma levels of BCKAs found in db/db mice.
In summary, our data indicate that classical or early-onset forms of type 2 diabetes are characterized by 
reduced expression of genes involved in BCAA metabolism. In addition, type 2 diabetes is linked to inhibition of 
BCKD complex in skeletal muscle. These alterations are also detected in muscles from diabetic db/db mice but 
not in obese ob/ob mice. Years ago the pyruvate dehydrogenase complex (PDC) was reported as an emerging 
target for the treatment of metabolic syndrome42. However, now we know that BCKAs inhibits its activity at least 
in muscle and liver38,39. In this regard, our data suggest that the alterations in muscle BCAA handling develop 
during the progression of type 2 diabetes, are relevant to cause the higher concentrations in circulating BCKAs.
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